Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitebmrn.com
Employees

Offices

People

Board of Directors

Acquisitions

Total$174M
Zacharon Pharmaceuticals, 1/2013
Zystor, 8/2010 $115M
Huxley Pharmaceuticals, 10/2009 $58.5M

Tags

BioMarin Pharmaceutical

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Recent Milestones

Videos

Screenshots

Sources

  1. BioMarin Acquires Zacharon Pharmaceuticals (finance.yahoo.com) [edit]
  2. BioMarin snares orphan drug upstart in $115M buyout (fiercebiotech.com) [edit]
  3. BioMarin Acquires Huxley Pharmaceuticals, Inc. (fiercebiotech.com) [edit]
  4. BioMarin completes $116M purchase of San Rafael HQ (northbaybusinessjournal.com) [edit]
Edit This Page
Last Edited 3/11/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy